# Prompts to LLM:

You are assisting a team of expert clinical pharmacists, drug interaction pharmacology researchers, and persons who edit drug interaction knowledge compendia. You help synthesize evidence about possible interactions between prescription drugs and natural products (botanical or herbal) based on the most recent and relevant information. Ground your response in factual data from your pre-train set or any context provided by the user, explicitly referencing or quoting authoritative sources when possible. In your response, think carefully and be specific about the source of the information used in each answer, and avoid citing sources if the information is not a direct citation from that source. Always explain your reasoning. Make it explicit when you base your reasoning on pharmacological inference rather than a direct citation from a textual source. Focus on factuality since you must evaluate your answer in the end. Structure your response using the following nine-item template: 

Item 1: A list of each potential mechanism, showing each step in your thinking and providing evidence to support each step involved.  

Item 2: A description of the natural product mentioned in the query. Please include a list of known names to refer to the product and note how it is prepared or consumed.  

Item 3: A summary of the pharmacokinetic properties of the natural product mentioned in the query. If available, include values for the Area Under the Curve change at therapeutic concentrations linked to a pharmacodynamic effect, information on common administration routes, and the average amount of bioactive compounds in the products. 

Item 4: A brief description of the drug mentioned in the query. Include a list of known names used to refer to the drug. 

Item 5: A summary of the pharmacokinetic properties of the drug mentioned in the query. If available, include values for the Area Under the Curve change at therapeutic concentrations linked to a pharmacodynamic effect, information on common administration routes, and standardized dosage of the drug's active ingredient.

Item 6: A summarized description of the adverse event mentioned in the query. List known potential causes and if the mentioned natural product or drug is associated with the adverse event. Include all available details regarding the average onset time of the adverse event. Include all available information regarding the likelihood of overlapping effects of the adverse event. Include all available details regarding the potential additive nature of the side effects involved in the adverse event. 

Item 7: A list and description of any mention of clinical importance for the interaction, including the frequency of the mentions. 

Item 8: A list of other drugs with similar pharmacodynamic and pharmacokinetic properties to the drug in the query that could interact with the natural product mentioned. 

Item 9: A list of other natural products with similar pharmacodynamic and pharmacokinetic properties to the natural product in the query that could interact with the drug mentioned.

Finally, classify how accurate your synthesis was. Rate your confidence in your answers on a scale of 1-5, 1 being very low and 5 being very high.


### Context ###


Include relevant items from the following information in your synthesis:
The Natural Product curcumin directly negatively regulates activity of the Enzyme or Transporter cytochrome P450 3A4 (human). The Drug tacrolimus (anhydrous) is substrate of the Enzyme or Transporter cytochrome P450 3A4 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event acute kidney failure. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:curcuma_longa Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_3962 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002449 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08684 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/DIDEO_00000041 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0002492

-----

The Natural Product curcumin interacts with the Enzyme or Transporter ATP-dependent translocase ABCB1 (human). The Drug tacrolimus (anhydrous) transports the Enzyme or Transporter ATP-dependent translocase ABCB1 (human). And the Drug tacrolimus (anhydrous) is causally correlated with the Adverse Event acute kidney failure. Natural Product Ontology Identifier: http://napdi.org/napdi_srs_imports:curcuma_longa Natural Product or Constituent Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_3962 Process Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002434 Enzyme or Transporter Ontology Identifier: http://purl.obolibrary.org/obo/PR_P08183 Process or Pathway Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002020 Drug Ontology Identifier: http://purl.obolibrary.org/obo/CHEBI_61049 Causal Relation Ontology Identifier: http://purl.obolibrary.org/obo/RO_0002610 Adverse Event Ontology Identifier: http://purl.obolibrary.org/obo/MONDO_0002492

### Query ###

What are the potential mechanisms that cause an interaction between Turmeric products and Tacrolimus that may cause Neurotoxicity?

-------

# Response from LLM:

Item 1: **Potential Mechanisms**  
- **Cytochrome P450 3A4 Inhibition**: Curcumin has been shown to negatively regulate cytochrome P450 3A4 (CYP3A4), which is responsible for metabolizing tacrolimus. Inhibition of this enzyme may lead to increased plasma concentrations of tacrolimus, resulting in potential neurotoxic effects due to its central nervous system (CNS) effects. 
- **Interaction with ABCB1 (P-glycoprotein)**: Curcumin also interacts with ABCB1, a transporter that extrudes tacrolimus from cells. Inhibition of this transporter would further increase the bioavailability of tacrolimus, thereby enhancing the risk of neurotoxic side effects.
- **Cumulative Toxicity**: With the overlapping effects of increased tacrolimus levels from both CYP3A4 inhibition and decreased transport, there is a theoretical cumulative toxic effect, especially in sensitive individuals, which might manifest as neurotoxicity.

Item 2: **Description of the Natural Product (Curcumin)**  
- **Known Names**: Curcumin, turmeric extract, or Curcuma longa.  
- **Preparation/Consumption**: Curcumin is commonly consumed as a spice (turmeric) in food, or as a dietary supplement in capsules or powders.

Item 3: **Pharmacokinetic Properties of Curcumin**  
- **Bioavailability**: Curcumin has low bioavailability due to poor absorption (around 1% in humans) and rapid metabolism.  
- **Common Routes**: Typically consumed orally.  
- **Concentration**: Standardized extracts may contain 95% curcuminoids, which include curcumin as the most active component.

Item 4: **Description of the Drug (Tacrolimus)**  
- **Known Names**: Tacrolimus (anhydrous), FK506, Prograf, Advagraf. 

Item 5: **Pharmacokinetic Properties of Tacrolimus**  
- **Bioavailability**: Tacrolimus has a bioavailability of approximately 20-25% when taken orally, with significant inter-individual variability.  
- **Common Routes**: Primarily administered orally, but can also be given intravenously.  
- **Standard Dosage**: Typical initial dosing for adults is usually around 0.1 to 0.3 mg/kg/day, adjusted based on therapeutic drug monitoring.

Item 6: **Summary of the Adverse Event (Acute Kidney Failure)**  
- **Known Causes**: Acute Kidney Failure can be caused by nephrotoxicity associated with immunosuppressive medications like tacrolimus.  
- **Association**: Tacrolimus is directly associated with acute kidney failure due to its nephrotoxic potential.  
- **Onset Time**: The onset of nephrotoxicity can occur within a few days to weeks after the initiation or dose adjustment of tacrolimus.  
- **Overlap Effects**: While curcumin's role in enhancing tacrolimus levels may not be causatively related to acute kidney failure, the potential increased bioavailability can contribute to this adverse event in patients concurrently using both.  
- **Additive Nature of Side Effects**: The effect of curcumin on tacrolimus levels may predispose to acute kidney injury, but direct additive effects on the kidneys from curcumin are not well established.

Item 7: **Clinical Importance of the Interaction**  
- **Frequency of Mention**: The interaction between curcumin and tacrolimus is clinically relevant, particularly for transplant patients. Increased levels of tacrolimus due to curcumin can be mentioned in pharmacology references, but specific incidence rates in clinical practice are limited and vary among individual cases. 

Item 8: **Other Drugs with Similar Properties**  
- **Similar Drugs**: Other drugs that are also metabolized by CYP3A4 and may thus have similar interactions with curcumin include:
  - Sirolimus
  - Midazolam
  - Atorvastatin

Item 9: **Other Natural Products with Similar Properties**  
- **Similar Natural Products**: Other herbal supplements that could interact with tacrolimus via similar mechanisms include:
  - St. John’s Wort (CYP3A4 inducer)
  - Ginseng (possible CYP and transporter interactions)

Confidence in synthesis: 5. The data is well-supported by existing literature on the pharmacokinetic interactions and adverse events associated with tacrolimus and curcumin.